Coherus BioSciences, Inc. (CHRS)
| Market Cap | 1.18B |
| Revenue (ttm) | 475.82M |
| Net Income (ttm) | 132.24M |
| Shares Out | 71.41M |
| EPS (ttm) | 1.62 |
| PE Ratio | 9.84 |
| Forward PE | 37.31 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $15.98 |
| Previous Close | $15.83 |
| Change ($) | 0.15 |
| Change (%) | 0.95% |
| Day's Open | 15.94 |
| Day's Range | 15.88 - 16.48 |
| Day's Volume | 1,340,167 |
| 52-Week Range | 10.86 - 22.22 |
Their recent struggles may soon give way to rising market interest and more lucrative returns.
REDWOOD CITY, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor confe...
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -52.00% and -3.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for t...
- Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 - - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration...
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA...
Shares of Redwood City, California-based Coherus BioSciences Inc. (NASDAQ:CHRS) are up about 13% just a week after announcing it has cut a $150 million deal with Chinese drugmaker Junshi Biosc...
REDWOOD CITY, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective January 21, 2021, the compensation ...
REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Bo...
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39th Annual J.P....
REDWOOD CITY, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 17, 2020, the compensation...
REDWOOD CITY, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective November 19, 2020, the compensation...
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q3 2020 Results - Earnings Call Transcript
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -5.71% and -5.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...
Coherus BioSciences (CHRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus BioSciences (CHRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released afte...
Coherus develops and markets biosimilar versions of blockbuster biologic products.
The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?
Coherus BioSciences' (CHRS) CEO Denny Lanfear on Q2 2020 Results - Earnings Call Transcript
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the s...
– Second Quarter UDENYCA® Net Sales of $135.7 Million – – Net Income of $59.0 Million – – Non-GAAP Net Income of $68.3 Million –
REDWOOD CITY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Direc...
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.
REDWOOD CITY, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released a...
The biosimilar leader has found quick success with its first major drug product, but the stock's performance hasn't seemed to reflect that.
One way to increase the chances of finding high-quality investments is to look for fairly priced stocks of companies that have good financial conditions and are expected to improve their net e...
Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q1 2020 Results - Earnings Call Transcript
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus: Branded Biosimilar Strategy, Cash Reserve, Revenue Stream
These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.
Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.
REDWOOD CITY, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the pricing of its offering of $200,000,000 agg...
REDWOOD CITY, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its intention to offer, subject to market and o...
COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020 COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020
Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.
Coherus BioSciences (CHRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
REDWOOD CITY, Calif., March 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective March 19, 2020, the compensation...
Coherus BioSciences: Current Weakness Represents A Buying Opportunity
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q4 2019 Results - Earnings Call Transcript
We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
REDWOOD CITY, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 18, 2020, the compensati...
Is (CHRS) Outperforming Other Medical Stocks This Year?
Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near ...
About CHRS
Coherus BioSciences, Inc., a biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid... [Read more...]
| Industry Biotechnology | IPO Date Nov 6, 2014 |
| CEO Dennis Lanfear | Employees 317 |
| Stock Exchange NASDAQ | Ticker Symbol CHRS |
Financial Performance
In 2020, CHRS's revenue was $475.82 million, an increase of 33.63% compared to the previous year's $356.07 million. Earnings were $132.24 million, an increase of 47.21%.
Analyst Forecasts
According to 10 analysts, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is 27.89, which is an increase of 74.53% from the latest price.